Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Carcinoma, Non-Small-Cell Lung 47Neoplasms 21Breast Neoplasms 19Triple Negative Breast Neoplasms 16Melanoma 15Urinary Bladder Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 13Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Solid Tumors 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Lymphoma 5Esophageal Neoplasms 5Stomach Neoplasms 4Lung Neoplasms 4Kidney Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Urologic Neoplasms 2Solid Tumor 2

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × atezolizumab × Clear all
NCT02926833 2024-03-06

ZUMA-6

Gilead Sciences

Phase 1/2 Completed
37 enrolled 28 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03276468 2023-01-10

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

The Lymphoma Academic Research Organisation

Phase 2 Completed
136 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Completed
91 enrolled 27 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡